These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18536113)

  • 41. [Can cardiovascular events be prevented by raising HDL cholesterol?].
    Langslet G; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel therapies for increasing serum levels of HDL.
    Toth PP
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):151-70. PubMed ID: 19217517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Don't overlook niacin for treating cholesterol problems. If you can conquer or cope with the "niacin flush," this B vitamin can do wonders for cholesterol.
    Harv Heart Lett; 2004 Apr; 14(8):4-5. PubMed ID: 15100082
    [No Abstract]   [Full Text] [Related]  

  • 45. The new margarines: can they help your heart?
    Harv Mens Health Watch; 2002 Feb; 6(7):1-4. PubMed ID: 11869985
    [No Abstract]   [Full Text] [Related]  

  • 46. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HDL: still a target for new therapies?
    Nicholls SJ
    Curr Opin Investig Drugs; 2008 Sep; 9(9):950-6. PubMed ID: 18729001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nicotinic acid and the prevention of coronary artery disease.
    Digby JE; Lee JM; Choudhury RP
    Curr Opin Lipidol; 2009 Aug; 20(4):321-6. PubMed ID: 19494772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
    Cybulska B; Kłosiewicz-Latoszek L
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II45-50. PubMed ID: 19813336
    [No Abstract]   [Full Text] [Related]  

  • 50. [Reverse cholesterol transport processes and their role in artherosclerosis regression].
    Chachaj A; Drozdz K; Szuba A
    Postepy Biochem; 2008; 54(3):301-7. PubMed ID: 19112829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reshaping the dyslipidemia management paradigm.
    Guthrie RM
    Postgrad Med; 2003 Aug; 114(2 Suppl):7-13. PubMed ID: 19667634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low HDL-cholesterol: Common and under-treated, but which drug to use?
    Wierzbicki AS
    Int J Clin Pract; 2006 Oct; 60(10):1149-53. PubMed ID: 16981959
    [No Abstract]   [Full Text] [Related]  

  • 53. Alpha lipoic acid possess dual antioxidant and lipid lowering properties in atherosclerotic-induced New Zealand White rabbit.
    Zulkhairi A; Zaiton Z; Jamaluddin M; Sharida F; Mohd TH; Hasnah B; Nazmi HM; Khairul O; Zanariyah A
    Biomed Pharmacother; 2008 Dec; 62(10):716-22. PubMed ID: 18538528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bridging the gap in treatment options for patients with hypertriglyceridemia.
    Underberg JA; Hays R
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S24-31. PubMed ID: 18664339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bibliography. Current world literature. Nutrition and metabolism.
    Curr Opin Lipidol; 2009 Feb; 20(1):63-72. PubMed ID: 19106709
    [No Abstract]   [Full Text] [Related]  

  • 57. Lipid screening and cardiovascular health in childhood.
    Daniels SR; Greer FR;
    Pediatrics; 2008 Jul; 122(1):198-208. PubMed ID: 18596007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2-{3-[2-(4-chlorophenyl)ethoxy]phenylthio}-2-methylpropanoic acid: a fibrate-like compound with hypolipidemic and antidiabetic activity.
    Dell'Uomo N; Tassoni E; Brunetti T; Pessotto P; Sciarroni AF; Milazzo FM; De Angelis F; Peschechera A; Tinti MO; Carminati P; Giannessi F
    ChemMedChem; 2006 Jan; 1(1):49-53. PubMed ID: 16892334
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 60. [Atherosclerosis: disputable and unsolved problems in the first decade of the XXI century].
    Kukharchuk VV
    Ter Arkh; 2009; 81(5):14-20. PubMed ID: 19537581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.